Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D04166 (
FeCl3
)
1,389
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Factor (F) XII, a key component of the contact system, triggers clotting via the intrinsic pathway, and is implicated in propagating thrombosis. Although nucleic acids are potent activators, it is unclear how the contact system is regulated to prevent uncontrolled clotting. Previously, we showed that
histidine-rich glycoprotein
(
HRG
) binds FXIIa and attenuates its capacity to trigger coagulation. To investigate the role of
HRG
as a regulator of the intrinsic pathway, we compared RNA- and DNA-induced thrombin generation in plasma from
HRG
-deficient and wild-type mice. Thrombin generation was enhanced in plasma from
HRG
-deficient mice, and accelerated clotting was restored to normal with
HRG
reconstitution. Although blood loss after tail tip amputation was similar in
HRG
-deficient and wild-type mice, carotid artery occlusion after
FeCl3
injury was accelerated in
HRG
-deficient mice, and
HRG
administration abrogated this effect. To confirm that
HRG
modulates the contact system, we used DNase, RNase, and antisense oligonucleotides to characterize the
FeCl3
model. Whereas DNase or FVII knockdown had no effect, carotid occlusion was abrogated with RNase or FXII knockdown, confirming that
FeCl3
-induced thrombosis is triggered by RNA in a FXII-dependent fashion. Therefore, in a nucleic acid-driven model,
HRG
inhibits thrombosis by modulating the intrinsic pathway of coagulation.
...
PMID:Arterial thrombosis is accelerated in mice deficient in histidine-rich glycoprotein. 2569 Nov 57